| Trial ID # | NCT01611558 |
| Phase | II |
| Drug Class | Immunotherapy: Checkpoint Inhibitors/CTLA-4 |
| Drug Name | Ipilimumab |
| Alternate Drug Names | Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy |
| Drugs in Trial | Ipilimumab |
| Eligible Participant | Platinum sensitive recurrence and PR, SD or PD in most recent chemotherapy, ≤ 4 prior therapies |
| Patients Enrolled | 49 |
| Therapy Setting | Recurrence |
| Study Design | Open-Label, Non-randomized |
| Endpoints | ORR, evaluated per RECIST |
| Efficacy | ORR: 10.3% (n=39) |
| Clinically Significant Adverse Events | Serious AE: 45% |
| Conclusion | Encouraging anti-tumor activity, but serious side effects observed |
| Reference | ClinicalTrials.gov, NCT01611558 |
Starting
January 1, 2025,
Clearity is joining
Ovarian Cancer
Research Alliance
(OCRA) and this website
will be redirected to
www.ocrahope.org
OCRA and Clearity are committed to serving the ovarian cancer community and providing the education, information, and support people need.